GSA Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $999K | Sell |
111,467
-167,085
| -60% | -$1.5M | 0.07% | 450 |
|
|
2025
Q1 | $2.09M | Buy |
278,552
+114,068
| +69% | +$855K | 0.19% | 58 |
|
|
2024
Q4 | $1.24M | Sell |
164,484
-121,104
| -42% | -$911K | 0.09% | 273 |
|
|
2024
Q3 | $2.17M | Sell |
285,588
-78,250
| -22% | -$595K | 0.16% | 101 |
|
|
2024
Q2 | $2.25M | Buy |
+363,838
| New | +$2.25M | 0.16% | 109 |
|
|
2024
Q1 | – | Sell |
-178,769
| Closed | -$1.07M | – | 1609 |
|
|
2023
Q4 | $1.07M | Sell |
178,769
-12,758
| -7% | -$76.4K | 0.09% | 355 |
|
|
2023
Q3 | $1.36M | Buy |
191,527
+119,995
| +168% | +$850K | 0.12% | 260 |
|
|
2023
Q2 | $504K | Sell |
71,532
-82,186
| -53% | -$579K | 0.05% | 723 |
|
|
2023
Q1 | $1.28M | Buy |
+153,718
| New | +$1.28M | 0.13% | 196 |
|
|
2022
Q4 | – | Sell |
-19,121
| Closed | -$241K | – | 1468 |
|
|
2022
Q3 | $241K | Buy |
+19,121
| New | +$241K | 0.03% | 1075 |
|
|
2021
Q4 | – | Sell |
-41,116
| Closed | -$591K | – | 1411 |
|
|
2021
Q3 | $591K | Buy |
+41,116
| New | +$591K | 0.06% | 597 |
|
|
2021
Q2 | – | Sell |
-80,197
| Closed | -$816K | – | 1320 |
|
|
2021
Q1 | $816K | Buy |
80,197
+69,697
| +664% | +$709K | 0.14% | 174 |
|
|
2020
Q4 | $78K | Buy |
+10,500
| New | +$78K | 0.01% | 1118 |
|
|
2020
Q3 | – | Sell |
-39,599
| Closed | -$189K | – | 1243 |
|
|
2020
Q2 | $189K | Sell |
39,599
-99,065
| -71% | -$473K | 0.11% | 367 |
|
|
2020
Q1 | $277K | Buy |
+138,664
| New | +$277K | 0.07% | 535 |
|
|
2019
Q2 | – | Sell |
-40,383
| Closed | -$329K | – | 1440 |
|
|
2019
Q1 | $329K | Buy |
+40,383
| New | +$329K | 0.03% | 942 |
|
|
2017
Q4 | – | Sell |
-13,086
| Closed | -$69K | – | 1554 |
|
|
2017
Q3 | $69K | Buy |
+13,086
| New | +$69K | ﹤0.01% | 1541 |
|
|
2015
Q1 | – | Sell |
-35,350
| Closed | -$430K | – | 2094 |
|
|
2014
Q4 | $430K | Sell |
35,350
-19,324
| -35% | -$235K | 0.03% | 1030 |
|
|
2014
Q3 | $535K | Buy |
+54,674
| New | +$535K | 0.03% | 895 |
|